Asabys Partners, a venture capital firm based in Barcelona and a member of Catalonia.health, has announced the launch of Oriva Therapeutics, a company dedicated to developing innovative therapies in women's health. The new company has integrated two advanced assets from Oncostellae and Medibiofarma, targeting two chronic diseases with high unmet medical need: endometriosis and uterine fibroids.
Funding Led by Sabadell Asabys II
Through its Sabadell Asabys II fund, Asabys has led the pre-seed financing round for the company to advance the clinical development of both assets. This operation positions Oriva Therapeutics as one of the first clinical-stage biotechnology companies in Spain with an exclusive focus on developing innovative medicines for the treatment of chronic gynecological diseases.
Two Advanced Therapeutic Programs
The first asset, ORV-362, is a non-hormonal disease-modifying therapy for the treatment of endometriosis, a condition that affects approximately 10% of women and girls of reproductive age worldwide. ORV-362 is compatible with conception and has demonstrated a favorable safety profile in clinical trials conducted by the originating company. The program entered Phase I in healthy women in January 2026.
The second program, ORV-499, is aimed at treating uterine fibroids, the most common benign gynecological tumors, and is expected to enter Phase I clinical trials in the first quarter of 2027. Both assets act on validated therapeutic targets and are based on innovative chemistry that clearly differentiates them from existing market options.
This funding from Sabadell Asabys II will enable Oriva Therapeutics to establish its initial team and facilities, as well as advance to Phase II clinical trials.
Clara Campàs, Managing Partner at Asabys, added: "Historically, chronic gynecological diseases such as endometriosis and uterine fibroids have been insufficiently funded and underserved, despite their profound impact on women's health. We are very excited to support Oriva in advancing these first-in-class and best-in-class programs toward the clinic and, ultimately, to patients. The high unmet medical need, together with the renewed interest of the pharmaceutical industry in chronic women's health indications and the extraordinary chemistry developed by Julio Castro and his team, make Oriva a highly promising investment for the Sabadell Asabys II fund."
Comments